Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) on Friday, April 11, announced that it has received final approval from the United ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ...

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited has received final approval from the United States Food and Drug ...

Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets in four strengths - 6 mg, 18 mg, 30 mg, and 36 mg.

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

India has 29 states with at least 720 districts comprising of approximately 6 lakh villages, and over 8200 cities and towns. Indian postal department has allotted a unique postal code of pin code ...

The Pincode 484330 of Jaithari P.O. represents Jaithari post office in Anuppur revenue district which comes under the Madhya Pradesh postal circle of Bhopal HQ region.

Jaythari is indicated for the treatment of DMD, a rare and genetic disease that results in ongoing muscle weakness and degeneration.